The use of the D 1 =D 2 dopamine receptor agonist apomorphine SL for the treatment of erectile dysfunction provides a strong support in favour of a participation of the dopaminergic system in the control of sexual function. However, the exact involvement of dopamine in sexual motivation and in the control of genital arousal in humans is unknown. In contrast, experimental data suggest an implication of dopamine at all these stages of the copulatory behaviour in rodents. The release of dopamine at the level of the nucleus accumbens, which is innervated by the mesolimbic dopaminergic pathway originating in the ventral tegmental area, is positively implicated in the pre-copulatory or appetitive phase in male rats. There is also a permissive role in the copulatory or consumatory phase for dopamine released at the level of the median pre-optic area, which receives projection from the dopaminergic incertohypothalamic pathway within the hypothalamus. It is noteworthy that these participations of the dopaminergic system are not specific to sexual behaviour but rather reflect the more general involvement of dopamine in the regulation of cognitive, integrative and reward processes. Due to its role in the control of locomotor activity, the integrity of the nigrostriatal dopaminergic pathway is also essential for the display of copulatory behaviour. Somehow more specific to sexual function, it is likely that dopamine can trigger penile erection by acting on oxytocinergic neurons located in the paraventricular nucleus of the hypothalamus, and perhaps on the pro-erectile sacral parasympathetic nucleus within the spinal cord. The counterpart of such regulation of the genital arousal by dopamine has not yet been established in females. In conclusion, the central dopaminergic system is a key element of the control of sexual function.
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Introduction
Penile erection is one component of a complex series of integrated physiological processes that encompass male sexual behaviour. Erection is a vascular event associated with tumescence of the cavernous bodies that relies upon integration of neural and humoral mechanisms at various levels in the neuroaxis. It is unique among visceral functions in that there is an absolute requirement for central neural input to ensure proper function; any perturbation of neural pathways can produce erectile dysfunction. Thus, the central nervous system (CNS) would be an extremely attractive target for any novel therapeutants. 1 Multiple potential sites have been identified in the CNS for active erectogenic drugs, based on modulation of neurotransmission within the synaptic cleft. From the perspective of the pharmaceutical industry, one of the most viable options is to attempt to mimic the actions of one of the key neurotransmitters. One such major neurotransmitter fundamentally involved in central processing of the integrated erectile response is dopamine.
Within the CNS, the master organ is the brain, which sends both activatory and inhibitory projections on the spinal centres driving the sexual organs. 2 To provide the overall co-ordinated control of the autonomic nervous system the brain utilises one of two broad anatomical strategies ( Figure 1 ).
These rely on either a hierarchical or a diffuse distribution of neural interconnections. Operating within these systems are several major neurotransmitters. Those neurotransmitters particularly relevant for the control of sexual function at the level of the (CNS) are serotonin (5-HT), norepinephrine, oxytocin, nitric oxide (NO) and dopamine (DA). 3, 4 Historically, the pro-sexual effect of DA in humans were first suggested by the observation of increased sexual activity in Parkinson's patient treated with DA agonists such as L-DOPA, the endogenous precursor of DA, although the incidence of such symptoms were very rare. 5, 6 Subsequently, several reports confirmed the ability of L-DOPA to induce erections. 7 -9 In one study, the ergot alkaloid bromocriptine, a reasonably selective D 2 agonist at the D 2 receptor subtype restored sexual functions in male hemodialysis patients. 10 Paradoxically, however, in early studies in patients suffering from erectile dysfunction (ED) of various aetiologies, bromocriptine was found to be of limited value in the treatment of male impotence unless hyperprolactinaemia was a component of the disease. 11, 12 The literature on DA receptor antagonists eg the neuroleptics is ambiguous. They have been reported to both impair erections and yet also to produce prolonged erection. 13 -15 However, several pilot studies have unambiguously demonstrated that the semi-synthetic DA D 1 =D 2 receptor agonist, apomorphine, could induce penile erections in healthy men and in men with ED. 16 -18 Overall, until the recent large-scale clinical trials on apomorphine, the link between sexual function and DA in man was tenuous. In contrast, numerous pharmacological studies have established a fundamental role for DA in the control of sexual function in both male and female rodents (for an extensive review see reference. 19 ) To help understand the clinical profile of apomorphine the animal data are described below.
DA synthesis, metabolism and receptors
The catecholamine family is constituted by DA, together with norepinephrine and epinephrine. With serotonin and histamine, they represent the main amines within the CNS. DA is synthesised from tyrosine in a two step reaction, involving first tyrosine hydroxylase (generating 3.4-dihydroxy-Lphenylalanine or L-DOPA) and second DOPA decarboxylase, generating DA. Conversion of tyrosine to L-DOPA and L-DOPA to DA occurs in the cytosol; DA is then taken up into storage vesicles. After release in the synaptic cleft, DA is actively taken back up from the extracellular space by specific transporters. In humans, the catabolic inactivation of DA is ensured principally (but not exclusively) by monoamine oxidase MAO A (as opposed to B) and catechol-o-methyl transferase (a comprehensive review is given in reference 20 DA is implicated in a wide range of physiological functions. For example, in Parkinson's disease, which is characterised by a degeneration of the nigrostriatal DA tract, there is a dramatic loss in the control of motor activity (for review see reference 21 ). On the other hand, neuroleptics, which are often effective in blocking hallucinations and delusions in schizophrenia, share the common property to be DA antagonists (for review see reference 22 ). Thus, DA is involved in the control of motor activity in the striatum but also in cognitive, emotional and reward processes in the limbic area. In this line, it has been proposed that DA neurons do not have specific functions but rather regulate and enable integrative functions in the neuronal system onto which they project. 23 Figure 4 represents a schematic diagram of the dopaminergic tracts in the rat brain and spinal cord discussed in this report. Involvement of DA in the ex copula control of penile erection
An ex copula experiment is performed in the absence of a sexual partner. As such, in males, experiments ex copula demonstrate the ability of a given compound to induce genital arousal (ie penile erection) without sexual stimuli. In this situation, the sexual motivation of the male rat, and hence its level of sexual arousal, is dependent on the receptive and proceptive behaviour of the female, which is a variable parameter.
The paraventricular nucleus (PVN) and penile erection
The PVN of the hypothalamus is richly innervated by DA neurons that belong to the incertohypothalamic system that in turn constitute part of the intrinsic DA innervation of the hypothalamus. 24, 25 The incertohypothalamic system is constituted by the A13 group in the rostral region of the medial zona incerta and the A14 group in the rostral periventricular nucleus. The incertohypothalamic system innervates various regions within the Cerebral cortex (low) Cerebral cortex (low) Cardiovascular system Retina *h ¼ human, r ¼ recombinant, **from radioligand binding studies, ***two forms identified defined on relative amino sequence length. Figure 4 Anatomical representation of the major dopaminergic pathways involved in the regulation of sexual function in the rat.
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hypothalamus, and notably the medial pre-optic area (MPOA) in addition to the PVN.
Injection of doses of apomorphine as low as 5 ng in the PVN can induce penile erections in freely moving rat without the presence of a female. 26 Similar responses are obtained when the selective D 2 agonist LY171555 is injected in place of apomorphine, but not with the D 1 agonist SKF38393. 26 Erections induced by direct central apomorphine injection into the PVN are abolished by systemic pre-treatment with the central D 1 antagonist, SCH23390, or the D 2 antagonist, sulpiride. 26 In anaesthetised rats, penile erections induced by peripheral delivery of apomorphine are antagonised by a preceding injection in the PVN of the D 1 receptor antagonist, SCH23390 or the D 2 antagonist, sulpiride. 27 These experiments are consistent with the pro-erectile action of apomorphine arising primarily from activation of DA receptors localised to the PVN. Consistent with this hypothesis is the finding that apomorphine injection into other hypothalamic structures, such as the ventromedial and dorsomedial nucleus, the pre-optic area or the nucleus accumbens did not induce penile erection. 26 The findings that in freely moving rats, apomorphine-induced erections are abolished by transection of the cavernous nerves 28 and are inhibited by the central DA antagonist haloperidol, whereas they are unaffected by the peripheral DA antagonist domperidone 29 are all consistent with a primary CNS action underlying the pro-sexual effect of apomorphine. In addition, intracavernosal injection of apomorphine failed to elicit penile erection 27 ruling out a direct action within the penile vasculature.
Overall, therefore, the pharmacology of the response leaves no doubt that the activation of neurons in the PVN can be considered as the sine qua non for the pro-erectile effect of apomorphine to occur, and this effect is mediated by DA D 1 and D 2 receptors. However, the link between DA and the pathophysiology of ED is more tenuous. Measurement of changes in DA release within the PVN concomitant to penile erection during copulation would be required to establish a link between DA=PVN and the induction of penile erection. Although, measurement of catecholamine turnover in the PVN has been shown to be feasible in rats, 30 it has not yet been performed before, during or after copulation.
The PVN does not seem to be involved in the control of reflexive erections, as erections elicited by retraction of the penile sheath in restrained male rats placed in a tube in a supine position were not affected by apomorphine injected into the PVN. 31 On the other hand, apomorphine injections facilitated seminal emission during penile reflex. 31 This was also the case when apomorphine was injected into the PVN prior to copulation experiments, although the dosing used (1 -10 mg) was far above the dosing necessary to induce penile erection. 32 The participation of the PVN in the control of seminal emission is further supported by the ability of electrical stimulations of the PVN to elicit the UG reflex. 33 There is some limited data suggesting that the central effects of apomorphine are mediated by oxytocin and NO ( Figure 5 ). There are oxytocinergic projections from parvocellular neurons in the PVN to the pro-erectile parasympathetic nucleus (SPN) in the spinal cord. 34 As oxytocin delivered at the level of the SPN induces penile erection in the anesthetised rat, the network PVN-SPN might represent a physiologic circuit involved in the generation of penile erection. 35 PVN apomorphine-induced penile erections in the freely moving rat can be antagonised by injection of an oxytocin antagonist intracerebroventriculary, but not locally, directly into the PVN. 36 It has been proposed that apomorphine-induced erections were mediated by the activation of the hypothalamic-septo-hippocampal oxytocinergic pathway. This proposal was based on: (1) the ability of median septum lesions to prevent the penile erection induced by apomorphine injection in the PVN; and (2) doses of apomorphine that induced penile erection increased the concentration of oxytocin in the hippocampus.
The role of NO in the CNS and in the central control of erectile function and sexual behaviour is not well documented. The inhibitor of NO synthase L-NAME given intracerebroventricularly (i.c.v.) prevented the occurrence of penile erection upon systemic injection of apomorphine. 37 The concentration of NO 2 7 in the PVN was increased by the injection of apomorphine or the D 2 agonist LY171555, which both induced penile erections. Whereas an inhibitor of NO synthase, L-NAME, inhibited both NO 2 7 and penile erection, oxytocin antagonists injected i.c.v. did not prevent the increase in NO 2 7 but did prevent the erectile Figure 5 Schematic representation of the involvement of dopaminergic pathways in the control of erectile function in the rat. 
Spinal cord and penile erection
Whereas the brain provided the overall integrated control of sexual function, the sexual response is ultimately controlled by spinal autonomic nuclei ( Figure 6 ). 3 Penile erection is caused by a change in the activity of efferent autonomic pathways to the erectile tissues ie a shift from an overall predominant sympathetic to parasympathetic outflow. The cell bodies of these autonomic neurons are located in the spinal cord at the thoracolumbar level for the sympathetic nuclei and at the sacral level for the parasympathetic nuclei (SPN).
The existence of DA projections from the A11 cell group to the spinal cord as well as an intrinsic DA innervation within the spinal cord raises the possibility of an additional direct action of apomorphine at the spinal level. 38, 39 Immunocytochemical studies revealed that DA fibres and terminals exist in virtually all laminae throughout the spinal cord. 40, 41 Furthermore, studies using ligand binding techniques have shown the presence of D 1 and D 2 receptors in the spinal cord. 42 In male rats, D 2 receptors identified with immunochemistry and in situ hybridisation have been located in the parasympathetic nucleus of the lumbosacral spinal cord, which contains the cellular bodies of the proerectile autonomic neurons innervating the penis. 43 D 2 receptors have also been found to be particularly abundant in the dorsomedian and the dorsolateral nucleus which innervate bulbospongiosus and ischiocavernosus striated muscles involved in penile rigidity in the rat. 43 In agreement with these anatomical findings, apomorphine delivered at the lumbosacral level with an intrathecal catheter elicited erectile activity in anesthetised rats. 44 In conscious rats, reflexive erections are depressed by peripheral injection of the non-specific DA agonist RDS-127 in normal and spinalised rats, and by intrathecal (i.t.) injection of apomorphine at the lumbosacral level. 45, 46 These results suggest that there may a spinal action for DA in the control of erection in addition to the one in the brain described above (the PVN and penile erection).
Control of female sexual motivation by DA
Female rat sexual behaviour A brief outline of some aspects of rat sexual behaviour is necessary for the understanding of the present report (for a review see reference 47 ). In classical copulation tests, or mating experiments, in which a male rat is in the presence of a receptive female, the male rat performs a succession of mounts with and without intromission before performing a mount with intromission and with ejaculation. At the same time, the female displays characteristic behaviours, such as a lordotic posture during mounts (a reflexive behaviour hormonally induced) and sequences of running away from the male with a characteristic gait (hopping and darting).
For the female, the lordosis quotient (number of lordotic posture=number of mounts by the male) reflects its receptivity. Lordosis can be considered as a passive behaviour of sexual motivation, whereas the hopping and darting sequences reflect its proceptivity or active behaviour of sexual motivation. Some data are in favour of a control of the female receptivity and proceptivity by DA.
Involvement of DA in female rat sexual motivation
Some studies showed that the lordotic response of ovariectomised estrogen-treated rats was increased by DA receptor blockers (such as sulpiride or spiroperidol) while it was decreased by DA agonists (such as apomorphine or piribedil). 48, 49 On the other Dopamine and sexual function F Giuliano and J Allard hand, apomorphine was found to be able to increase the lordotic response of ovariectomised rats treated with oestrogen and progesterone when given systemically. 50 Stimulation of D 2 receptors by either LY171555 or LY163502 was also found to increase the lordotic response of low receptive ovariectomised oestrogen treated rats. 51 D 2 agonists can also increase proceptivity counts. 52 In contrast, selective D 1 agonists and antagonists do not affect measures of proceptivity and receptivity in female rats. 49, 51 However injections in discrete brain areas can reveal an effect of D 1 agonist=antagonist on lordosis. For example, a D 1 receptor agonist, but not a D 2 receptor agonist, infused i.c.v., mimicked the effects of progesterone in facilitating sexual behaviours in oestrogen primed, ovariectomised female rats. 53 A possible explanation to reconcile this discrepancy is that low doses of DA agonists facilitate the lordotic responses in low receptive female rats, while high doses decrease the lordotic response in fully receptive female rats. However, it is noteworthy that the sexual steroids oestrogen and progesterone exert marked effects on the DA system. Ovariectomy or steroid treatment have been reported to induce changes in DA content and turnover 54, 55 and in the density of DA receptors. 56, 57 Experiments with neurochemical lesions of the mesolimbic DA pathways with 6-hydroxydopamine could not lead to straight conclusions. Some experiments showed a facilitation of lordosis behaviour upon lesions, 58 while others found no effect on either lordosis or proceptive behaviour. 59 Microdialysis experiments have shown that DA levels in the MPOA rose at the time sexual receptivity is initiated by hormonal priming in females. In addition, there is a further increase in DA release when the male and female rats are allowed to copulate, but not when they are physically separated. 60 This is an argument for a physiological role of DA in the appetitive phase of sexual behaviour in female rats.
Control of male sexual motivation by DA
Results from classical mating experiments
For the male, the latency for the first intromission can be considered as a parameter reflecting the motivation of the male rat to copulate. DA agonists systemically delivered such as apomorphine, bromocriptine, pergolide or lisuride facilitates copulation in males in the presence of receptive females (decreased the intromission latency), and lowered the ejaculatory threshold (decrease in intromission number and ejaculation latency). 19 Results from classical copulatory experiments support a positive involvement of DA in the nucleus accumbens in the anticipatory phase of sexual behaviour. The mesocortical=mesolimbic pathway innervates the nucleus accumbens. The mesocortical=mesolimbic pathway is constituted by the DA cell bodies that lie medial to the substantia nigra (ventral tegmental area, A10). They provide a diffuse innervation to the forebrain, including frontal and cingulate cortex, septum, nucleus accumbens and olfactory tubercle.
Injection of apomorphine in the nucleus accumbens decreased the latency to begin copulating in copulatory experiments, but not when injected in the septum or the striatum. 61 In agreement, Damphetamine, which induces release of DA from nerve terminals, significantly decreased mount and intromission latency when injected in the nucleus accumbens, without affecting mount number and ejaculation latency. 62, 63 Conversely, injection of apomorphine in the ventral segmental area increased intromission latency, probably inhibiting the mesolimbic DA pathway through stimulation of autoreceptors, and thus decreasing DA transmission at the level of the nucleus accumbens. 64 
Necessity for alternative tests to the classical mating experiment
In spite of these findings with DA agonists in mating experiments, DA antagonists were found to have no effect on intromission or ejaculation latencies when injected in the nucleus accumbens in copulatory experiments when paired with fully receptive females. 62, 65 In contrast, when females were treated with flupenthixol that eliminated proceptive behaviour, the D 2 antagonist raclopride decreased the mount and intromission latencies when injected in the nucleus accumbens, but not in the dorsal striatum. 62 This demonstrates that the appetitive behaviour of the male rat also relies upon the females behaviour, or in other words a fully sexy, lubric and demonstrative female will overcome the specific antagonistic effect of a given drug on the anticipatory behaviour of the male rat. A corollary of this finding is that the classical copulatory experiment definitely does not allow complete discrimination of appetitive and consumatory behaviour.
Indeed, it is not well accepted that classical studies in which the male and the female continuously interact in one way or another do not allow the appetitive, or incentive motivational, component of sexual behaviour to be clearly studied independently of the ability to copulate. The male rat is continuously teased by the proceptive behaviour of the female, and the female is also affected by the exploratory behaviour of the male.
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Control of sexual motivation in the nucleus accumbens by DA Specific tests have been developed to discriminate the appetitive from the consumatory component of sexual behaviour, such as the bilevel chambers. In this test, the male rat chases the female from one level to another after each intromission. The number of level changes in a fixed time before the introduction of the female is considered a measure of the anticipatory phase (or motivation) of sexual activity. Such tests evidenced that DA plays a role in the anticipatory or appetitive phase of the sexual behaviour in male rats. 66 Using the bilevel chamber paradigm, it has been shown that bilateral infusions of haloperidol (a D 2 > D 1 antagonist) into the nucleus accumbens reduced the anticipatory=preparatory phase of copulatory behaviour but did not affect the consumatory measures of copulation. 65 In contrast, infusion of haloperidol in the MPOA reproduced all the effects of systemic administration, ie decrease of the anticipatory=preparatory and consumatory phase of copulatory behaviour. 65 Such results suggest a positive involvement of DA in the nucleus accumbens in the anticipatory phase of sexual behaviour.
DA measurement supports a physiological role of DA in the nucleus accumbens in male rat sexual behaviour. Extracellular DA increased in the nucleus accumbens when an oestrous female was presented behind a barrier, as well as during copulation. 65 Exposure to a non-oestrous female did not elicit DA release. 67 Thus, DA plays a positive role in the anticipatory phase in male rats at the level of the nucleus accumbens.
Control of sexual performance by DA
Medial pre-optic area (MPOA)
The MPOA is innervated by the incertohypothalamic pathway, which originates from the A14 group. First, it is noteworthy that destruction of the MPOA destroys male copulatory behaviour but not the occurrence of spontaneous erection or penile erection upon penile reflex. 68 Instrumental measures of sexual motivation were achieved by training males to work for an oestrous female, presented in an operant chamber under a second-order schedule of reinforcement. MPOA lesions abolished mounts, intromissions and ejaculation but did not disrupt instrumental responses, investigation of the female, or abortive mounting attempts. 69 Injection of apomorphine in the MPOA reproduced the facilitatory effects seen on copulatory behaviour in intact rats, 70 ie decreased mount latency and increased number of ejaculations of rats that copulate. We have already mentioned that infusion of haloperidol in the MPOA reproduced all the effects of systemic administration of haloperidol, ie decrease of the anticipatory= preparatory and consumatory phase of copulatory behaviour. 65 These data indicate a preponderant role of the MPOA in the performance of sexual behaviour, although a role in sexual motivation cannot be completely ruled out. The major efferent projections of the MPOA are to hypothalamic, midbrain, and brain stem nuclei that regulate autonomic or somatomotor patterns and motivational state. 71 It has been postulated that the MPOA removes the tonic inhibition on these patterns and thereby allows sensory stimuli to elicit a motor response.
The stimulatory role of DA in the medial preoptic area in physiological conditions has been confirmed as DA and DOPAC were shown to be increased during the precopulatory phase and during copulation, and lowered after ejaculation. 72 Note that the increase in DA level in the MPOA during the precopulatory phase underlines a potential role in the anticipatory phase, in addition to its wellestablished role on performance.
Thus, DA participates at the level of the MPOA in the control of performance and may also affect sexual motivation, although to a lesser extent or less clear extent than the nucleus accumbens.
Striatum
The nigrostriatal pathway is the major DA tract. It originates in the zona compacta of the substantia nigra (A9) and sends axons that provide a dense innervation to the caudate nucleus and putamen of the striatum (nearly 80% of all the DA in the brain is found in the corpus striatum). The nigrostriatal system plays a key role in the initiation and control of movement, as emphasised in Parkinson's disease.
Apomorphine injected into the striatum was without effect on copulation in male rats. 61 In the bilevel chamber paradigm, high doses of systemic haloperidol delayed or abolished level changing and the initiation of copulation probably by impairing motor performance by blocking DA receptors in the striatum. 65 Bilateral infusions of haloperidol into the striatum only increased the number of ejaculations in the bilevel chamber paradigm, possibly because the striatum is a rather large structure that needs a considerable amount of drug to be fully affected. 66 DA is released in the dorsal striatum only after the male begins to copulate, suggesting that here, DA levels reflect primarily motor activation, rather than motivational aspects of copulation. 73 In contrast, forced locomotion on a rotating drum, exposure to a Dopamine and sexual function F Giuliano and J Allard novel chamber, and exposure to sex odours did not increase DA significantly in the striatum, although both DOPAC and HVA increased significantly in both regions during the locomotion test. 73 Thus, there is some specificity in the release of DA in the striatum during copulation.
In humans
The only direct argument supporting the involvement of the DA system in human sexual function comes from the extensive clinical efficacy of apomorphine SL in ED patients. 74, 75 However, the extensive work described in this article in rodents, lends support to the 'DA theory' of the control of human sexual function. In addition, non-human primate studies showed that apomorphine and LY163502 are capable of facilitating sexual behaviour of male rhesus monkeys only in the presence of a receptive female they could at least see and smell. 76, 77 Interestingly, no facilitator effect was seen in the absence of females.
Highly innovative magnetic resonance imaging (MRI) studies have given some insight into the brain structures involved in sexual arousal induced by apomorphine. In a study with six patients with a history of psychogenic ED, it was shown that the inferior temporal regions on the right, superior prefrontal cortex and posterior parietal regions bilaterally, and the thalamus, were specifically activated upon sub-lingual administration of apomorphine. 78 In comparison, visually evoked sexual arousal (without drug treatment) was characterised by: bilateral activation of the inferior temporal cortex, a visual association area; activation of the right insula and right inferior frontal cortex, which are two paralimbic areas relating highly processed sensory information with motivational state; and activation of the left anterior cingulate cortex, another paralimbic area known to control autonomic and neuroendocrine functions. 79 However, further experimentation is required. In particular it would be of value to determine to what extent apomorphine activates brain structures that are quiescent in sexual arousal that occurs in the absence of drug induction or facilitation.
It has been demonstrated in rats that the DA system is involved to varying extends at all satges in the control of the sexual function, from the appetitive to the consummatory phase. It is probable that this is also the case in humans. Thus, the prosexual action of apomorphine is likely to be much more complex than the simple triggering of penile erection. Nevertheless, in clinical trials with sub-lingual apomorphine, there was no major effect on sexual desire as measured by the IIEF questionnaire. 80 Paradoxically, however, apomorphine has been shown to increase libido in psychiatric patients. 81 An effect of apomorphine on sexual desire would be of special interest for the treatment of female sexual dysfunction.
Conclusion
Penile erection is a complex behavioural response that is dependent on the interaction of several diverse humoral and neural events at various levels of the neuroaxis. Existing therapies act mainly by the production of localised vasodilation in the penis by augmentation of the NO system or attenuation of the counterbalancing sympathetic nervous system. However, the CNS that initiates signalling to the penis and integrates the overall response has a prime role in the normal sexual response. Several lines of evidence indicate that the central dopaminergic system has a major role in the control of sexual function and normal erectile activity in both animals and man. It is likely, at the level of the hypothalamus, that these dopaminergic systems are fundamentally involved in the production of the normal integrated response that results in penile erection. Apomorphine acts on DA receptors to rectify abnormal pathophysiology in the ED patient and thereby restore normal erectile function.
DA is particularly involved in the appetitive= anticipatory phase of sexual behaviour in the nucleus accumbens and in the consumatory phase in the dorsal caudate-putamen. This is consistent with the more general role of DA in emotion and cognitive function in limbic areas and in the control of movement in the striatum, respectively. In the MPOA, DA plays a permissive role in the expression of copulatory behaviour. Eventually, DA is probably involved in the triggering of the erectile response at the level of the PVN and possibly in the lumbosacral spinal cord.
